On 16 August 2024, Bio-Thera announced that it has entered into a licensing and supply agreement with Pharmapark for BAT2306, biosimilar to Cosentyx® (secukinumab). Under the agreement, Pharmapark will have exclusive rights to distribute and market BAT2306 in Russia and other CIS countries. This expands upon existing agreements between the two companies in relation to biosimilar golimumab, BAT2506, and BAT2206, an ustekinumab biosimilar.
Bio-Thera commenced a phase 3 clinical trial of BAT2306 in November 2022, which is estimated to be completed in the second half of 2024.
Earlier this week Celltrion announced that it had received FDA approval for its global phase 3 clinical trial of its own Cosentyx® biosimilar, CT-P55. The FDA approved Novartis’ Cosentyx® in October 2023 for moderate to severe hidradenitis suppurativa. Cosentyx® was also approved in June 2023 by EMA for the same indication.